Assenagon Asset Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Assenagon Asset Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,350,558	Closed	-$27.2M	–	1613
2021 Q3	$27.2M	Buy	1,350,558 +780,152	+137%	+$21.5M	0.09%	176
2021 Q2	$21.3M	Buy	570,406 +555,218	+3,656%	+$17M	0.07%	216
2021 Q1	$388K	Sell	15,188 -118,184	-89%	-$3.02M	﹤0.01%	1064
2020 Q4	$2.94M	Sell	133,372 -14,028	-10%	-$309K	0.01%	447
2020 Q3	$2.65M	Buy	+147,400	New	+$3.05M	0.01%	517
2020 Q2	–	Sell	-191,758	Closed	-$3.52M	–	1285
2020 Q1	$3.52M	Buy	+191,758	New	+$3.73M	0.03%	259
2019 Q2	–	Sell	-307,262	Closed	-$4.5M	–	1228
2019 Q1	$4.5M	Buy	+307,262	New	+$3.53M	0.04%	335

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Assenagon Asset Management's DRNA Position: Q4 2021 in Review

Assenagon Asset Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 1,350,558 shares — an estimated $27.2M sold.

Assenagon Asset Management first reported a position in DRNA in Q1 2019 and held it in 7 quarters. The position peaked at $27.2M in Q3 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Assenagon Asset Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Assenagon Asset Management sold 1,350,558 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $27.2M.
Assenagon Asset Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2019 and held it in 7 quarters.
Assenagon Asset Management's Dicerna Pharmaceuticals, Inc. position peaked at $27.2M in Q3 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Assenagon Asset Management's 13F filing for Q4 2021, filed 1 Feb 2022.